Bachem GMP Custom Peptide Synthesis and Custom Peptide Manufacturing

Technology-based peptide chemistry solutions

Bachem provides technology-based peptide chemistry solutions. The company offers a comprehensive range of services throughout the pharma and biotech industries.

It is a specialists developer of innovative, efficient manufacturing processes, as well as dependable production of peptide-based active pharmaceutical ingredients. Its services portfolio is completed by a complete range of biochemicals and exclusive custom syntheses for research labs.

The group has its headquarters in Switzerland, with subsidiaries in Europe and the US giving it a truly global reach. Customers can be assured of quality and innovation.

Bachem. Pioneering Partner for Peptides

Custom peptide synthesis

In the business segment research chemicals (which accounts for 20% of Bachem’s sales revenue) Bachem offers peptide custom synthesis and products that are marketed through the Bachem catalogs, containing more than 9000 products available from stock.

Bachem’s range of products is focused on peptide building blocks, natural and unnatural speciality amino acids, peptide fragments, an impressive list of neuropeptides, peptide inhibitors, peptide substrates, and complex organic molecules, as well as resins and linkers for peptide synthesis.

Custom peptide manufacturing

Bachem has the required capacity for custom peptide manufacturing of new active ingredients for the biotech and pharmaceutical industry that are either in clinical development or have already been approved for commercial use.

These new chemical entities (NCEs) must be produced and analyzed in accordance with the rules of GMP. Bachem offers its peptide custom manufacturing and the related services from the early preclinical phase onwards. Bachem offers them at such an early stage so that an optimal basis can be created for a reliable partnership with the customer right up to market approval and beyond. This business segment accounts for 50% of Bachem’s sales revenue.

Generic active pharmaceutical ingredients

Bachem supplies peptides and organic active ingredients whose patent protection has lapsed. This business segment accounts for 30% of Bachem’s sales revenue.

Further opportunities for growth with peptide and complex organic active ingredients lie with new innovative forms of delivery, such as sustained release depots. Bachem’s customers can apply for patent protection for these depots, giving them a potential similar to that of new chemical entities.

In this field, Bachem offers:

  • Leuprolide, Goserelin, Gonadorelin, Triptorelin, Histrelin, Fertirelin, Nafarelin, Antide, Buserelin, Deslorelin
  • Calcitonin, Elcatonin, GRF, CRF, Thymopentin, Thymosin
  • Aviptadil, Glucagon, GLP-1 (7-37), Ghrelin, Peptide YY, Peptide YY (3-36), Somatostatin, Octreotide, Sincalide, Secretin
  • Desmopressin, pTH (1-34), Protirelin, Angiotensin, Splenopentin, Endothelin, IGF-1, Dynorphin A, Terlipressin, Tetracosactide, -Melanotropin
  • Carbidopa, Etomidate, Zonisamide, Propofol, Xylazine, Antazoline, Acetylcysteine, Carbocysteine, Pergolide, Trandolapril, Trimetazidine, Xipamide

Finished dosage form

For its peptides, Bachem does not offer the API only, but also the finished dosage form (FDF). Through Bachem’s fully owned subsidiary in Germany, clinical trial materials in vials, ampoules and pre-filled syringes – released by Bachem’s Qualified Person (QP) – are available (Clinalfa® brand).

This service supports our customers’ needs and shortens time-to-market: from research grade chemicals and peptide custom synthesis, to custom synthesis of complex organic molecules, GMP peptide manufacturing of NCEs, and generic peptides and peptides in their finished dosage form.

Custom manufacturing of cytostatic and cytotoxic compounds

Bachem has extended its product offering with custom manufacturing of cytostatic and cytotoxic peptides and complex organic molecules. These substances are used as active ingredients for cancer therapy and have to be manufactured according to the strictest safety requirements for both staff and the environment.

Full regulatory support

Bachem has the experience and the financial resources to meet growing regulatory and GMP demands. We have also submitted dozens of technical packages in support of successful IMPD and IND applications.

Make an enquiry

Follow this company

Follow the company to be always up to date with this company

Press Release

Seven New Products Now Available from Bachem

Bachem is continuously expanding and updating its extensive range of products for your research purposes.

White Papers

Melusine Venom Libraries: Designed to Discover Tomorrow’s Drugs

Melusine Venom Libraries are high-quality venoms prepared and pre-fractionated on an automated platform and dispensed in micro-plates ready for high throughput screening (HTS) in targeted lead discovery projects.

Address
Bachem AG

Hauptstrasse 144

CH-4416 Bubendorf

Other

Switzerland

+41 61 935 2333 +41 61 935 2325 Online Catalogue www.bachem.com

Bachem Images

Products and Services

Video

Press Release

17 May 2013

Bachem is continuously expanding and updating its extensive range of biologically active peptides, amino acid derivatives, biochemicals and immunology products.

Read more
9 April 2013

Bachem and Axon Neuroscience SE today announced that the two companies have entered into a collaboration under which Bachem manufactures Axon's investigational API and supplies it as a finished dosage form under Bachem's Clinalfa brand.

Read more
14 March 2013

Bachem is continuously expanding and updating its extensive range of biologically active peptides, amino acid derivatives, biochemicals and immunology products.

Read more
21 January 2013

Bachem is continuously expanding and updating its extensive range of products for your research purposes.

Read more
5 November 2012

The Japanese Ministry of Health, Labour and Welfare (MHLW) has granted Bachem AG a renewed manufacturing licence in conformity with their regulations.

Read more
17 September 2012

Bachem is continuously expanding and updating its extensive range of products for your research purposes.

Read more
24 August 2012

Bachem Group reported sales of 76.2m CHF for the first half of 2012.

Read more
19 October 2011

To enable quantitative studies of enzyme kinetics, enzyme substrates have been manufactured bearing chromogenic or fluorogenic moieties to allow for visualization using ultraviolet absorption and/or fluorescence spectroscopy.

Read more
17 March 2011

Bachem is continuously expanding and updating its extensive range of products for your research purposes. We are pleased to present our latest product additions, which include several Pro-VGF-derived peptides, osteoblast activating peptides, and two deuterium-labelled API analogs. A number of pro

Read more
8 March 2011

Fujifilm Corporation and Merck, known as MSD outside the US and Canada, have announced that they have entered into a definitive agreement by which Fujifilm will acquire the Merck BioManufacturing Network, a leading provider of contract manufacturing and development services for the biopharmaceut

Read more
12 January 2011

Bachem is continuously expanding and updating its extensive range of products for your research purposes. We are pleased to present our latest product additions, which include H-Pro-Gly-Pro-OH (PGP), a physiological substrate for the aminopeptidase activity of leukotriene A4 hydrolase and immunol

Read more
16 November 2010

Bachem is continuously expanding and updating its extensive range of products for your research purposes. We are pleased to present our latest product additions, which include human C5a Anaphylatoxin, the deuterium-labelled octreotide analog ([ring-D5]Phe³) - Octreot

Read more
26 September 2010

ARTES Biotechnology announces today the acquirement of the ANAVAX virus-like particle (VLP) technology from Select Vaccines. ANAVAX is a patent-protected VLP technology that can be applied to the prevention of several infectious diseases. With the combination of two excellent technolog

Read more
13 September 2010

Bachem has announced that the company has concluded an agreement with Atheris Laboratories to market their Melusine® libraries, consisting of natural products isolated from animal venoms. The agreement includes services to assist customers with the identification of the active ingredients a

Read more
1 September 2010

Solid-phase synthesis, especially the more convenient Fmoc variant, has become the routine method for assembling peptides. Standard resins such as Wang resin yield the 'free peptide', whereas resins such as SASRIN™ or 2-chlorotrityl resin have been developed for the option to keep protection

Read more
22 August 2010

In the first half of 2010, sales of the Bachem Group fell to CHF73.9m as a result of the difficult market conditions. Trends in the most important business areas Generics in particular showed a sales decline of 27.4% in local currencies (LC) as a result of various

Read more
18 July 2010

Bachem is continuously expanding and updating its extensive range of products for your research purposes. We are pleased to present our latest product additions, which include atrial natriuretic factor (1-28) (human), the NPY Y4 receptor-selective agonist DL-2,7-Diaminosuberoyl-((TyrRead more

23 June 2010

Thymosin β4 is a 43 amino acid peptide. It is the most abundant member of the β-thymosin family in mammalian tissue and is regarded as the main intracellular G-actin sequestering peptide. Thymosin β4 has multiple biological activities including prevention of apoptosis, reduction of

Read more
21 June 2010

Bachem has announced that the company, on 16 June 2010, sold its complete stake in Polyphor to Ingro Finanz, which hereby increased its stake in Polyphor to 29%. The involved parties have agreed not to disclose the purchase price of the transaction. For more than ten years Bachem

Read more
2 June 2010

Bachem and ISA Pharmaceuticals have announced the conclusion of an agreement for the manufacture of the active ingredients and the supply of finished dosage forms of ISA Pharmaceutical's immunotherapeutic HPV-SLP® product. The company has successfully concluded a clinical phase II

Read more
28 April 2010

Q Chip and ARTES Biotechnology have announced that they have signed a collaborative agreement to explore the co-development of a new sustained release formulation of interferon alpha 2a for the treatment of chronic hepatitis B and C. The study is designed to evaluate Q Chips' Q-Sphera&

Read more
21 April 2010

The complex formation between biotin and avidin or streptavidin is one of the strongest and most specific non-covalent interactions of a low-molecular weight compound with a protein. In practical use, the non-glycosylated streptavidin is preferred over the glycoprotein avidin as it shows less uns

Read more
23 March 2010

Bachem is continuously expanding and updating its extensive range of products for your research purposes. We are pleased to present our latest product additions, which include the PAC1 receptor antagonist M65, the opioid peptide Gliadorphin-7, additional pseudoprolines, and several high-sensitivi

Read more
18 March 2010

In 2009, despite difficult market conditions, the Bachem Group achieved sales of CHF181.8 million. Compared with the previous year, this corresponds to a sales decline of only 5.6% in local currencies. The mid-year deficit compared with the previous year’s period was therefore substantially

Read more
10 February 2010

Bachem, the number one in the production of peptides at any scale, is and will remain your ideal partner for custom synthesis. Our proficient peptide synthesis techniques coupled with high capacity and efficient production equipment result in swift delivery and superior quality. Our de

Read more
13 January 2010

Bachem is continuously expanding and updating its extensive range of products for your research purposes. We are pleased to present our latest product additions, which include Liraglutide, a GLP-1 analog, the rat alarin sequence, a range of ACTH peptides, and a high sensitivity EIA kit for the de

Read more
18 November 2009

Bachem is continuously expanding and updating its extensive range of products for your research purposes. We are pleased to present our latest product additions, which include the novel biomarker copeptin, 6-Azido-hexanoic acid for 'click chemistry' and several other building blocks, the non-ioni

Read more
16 November 2009

ARTES Biotechnology, specialised in recombinant protein production and process development from yeast expression systems, and Rhein Minapharm Biogenetics, a subsidiary of Minapharm SAE, jointly announced the successful production of a new target of a therapeutic protein. This was the first result

Read more
18 October 2009

The coupling reaction is the critical step in peptide synthesis. In particular, the solid-phase approach relies on rapid peptide bond formation and complete conversion with a minimum of concomitant side-reactions such as racemization. To meet these requirements a plethora of coupling (

Read more
18 October 2009

mondoBIOTECH and Bachem have announced the conclusion of a longterm cooperation. In the frame of the agreement with Interferon Medical Use in Collina d'Oro, Switzerland - a 100% affiliate of mondoBIOTECH Holding - Bachem provides its comprehensive know-how on peptides and its longstanding exp

Read more
22 September 2009

Bachem is continuously expanding and updating its extensive range of products for your research purposes. We are pleased to present our latest product additions, which include a number of bioactive molecules, synthetic RANTES peptides, several LHRH impurities and a range of new immunology product

Read more
1 September 2009

ARTES Biotechnology has announced its collaboration with five other collaboration partners in a joint 28-month research programme that is granted by the national Deutsche Stiftung Umwelt within the ChemBioTec initiative. The Deutsche Bundesstiftung Umwelt DBU is one of Europe's largest foundation

Read more
5 August 2009

ARTES has announced that it has signed an exclusive marketing agreement with the Institute of Cell Biology of the National Academy of Science of Ukraine. The agreement is that the NAS technology based on the yeast organism Hansenula polymorpha is now exclusively marketed and licensed by ARTES Bio

Read more
10 May 2009

ARTES Biotechnology has announced its collaboration with Henkel in a joint three-year research programme that is granted by the German national BMBF (German Ministery of Education and Research) within the CLIB2021 cluster (Wettbewerb Industrielle Biotechnologie 2021). The cooperation aims to adva

Read more
14 January 2008

ARTES Biotechnology, which specializes in recombinant protein production from yeast expression systems, and Rhein Minapharm Biogenetics, a subsidiary of Minapharm, jointly announced the start of a strategic collaboration to develop three therapeutic proteins. Financial details were not disclosed.

Read more
8 October 2007

ARTES Biotechnology GmbH expands technology platform Having achieved notable success with the Hansenula technology for years, the biotech company ARTES has now concluded an exclusive partnership with the internationally renowned Leibniz Institute of Plant Genetics and Crop Plant

Read more
17 July 2007

"We are looking forward to working with an international team“, says Dr Melanie Dröttboom, head of business development of Artes Biotechnology GmbH. Biotech company Artes, based near Düsseldorf, has been confirmed that it is developing an aptamer-based microarray for

Read more
29 May 2007

ACE Pharmaceuticals today announced that the first patient has entered the Phase III trial also known as the Levamisole trial. This trial was accepted by the EMEA by November 2006. The goal of this trial, which was accepted by the EMEA in November 2006, is to assess the efficacy and sa

Read more
9 January 2007

ARTES announces the grant of the European patent on increasing recombinant protein secretion in yeast by co-expression of Calnexin, a protein responsible in intracellular quality control and sorting. In extensive studies, ARTES could show that overexpression of Calnexin results in sign

Read more
19 June 2006

Kiel - Erkrath, June 19, 2006. PROTEO Biotech AG, a wholly owned subsidiary of PROTEO Inc., USA, has signed a cooperation agreement with ARTES Biotechnology GmbH. The aim of the agreement is the marketing of Elafin, the lead product of PROTEO Biotech AG / PROTEO Inc., in India, Egypt and Argentin

Read more

Regional Offices

Bachem (UK) Ltd

Delph Court

Sherdley Business Park

Merseyside

Sullivans Way, St. Helens

WA9 5GL

Other

United Kingdom

+44 1744 61 2108 +44 1744 73 0064
Peninsula Laboratories, Inc.

305 Old County Road

San Carlos

California

94070

Other

United States of America

+1 650 592 5392 +1 650 595 4069
Bachem Americas

3132 Kashiwa Street

Torrance

California

90505

Other

United States of America

+1 310 539 4171 +1 310 530 1571
Bachem Bioscience, Inc.

3700 Horizon Drive

King of Prussia

Pennslyvania

19406

Other

United States of America

+1 610 239 0300 +1 610 239 0800
Sochinaz SA

Route du Simplon 22

1895 Vionnaz

Other

Switzerland

+41 24 482 4444 +41 24 482 4445
Bachem Distribution Services GmbH

Hegenheimer Strasse 5

79576 Weil am Rhein

Other

Germany

+41 61 935 2323 +41 61 935 2325
Bachem AG

Hauptstrasse 144

CH-4416 Bubendorf

Other

Switzerland

+41 61 935 2333 +41 61 935 2325 Online Catalogue www.bachem.com

Contact company

I have read and accept the terms and conditions and privacy policy.
We'd like to keep you informed about relevant promotions, products and services, if you would like not to receive these, check this box.
If you would like to hear from carefully selected third party companies, check this box
Follow this company to receive notifications when they update.